Metalead

MetaLead is a pioneering company in the field of medicinal inorganic chemistry, focusing on the development of next-generation medications to treat lead poisoning. The company operates in the healthcare and pharmaceutical market, serving patients affected by lead toxicity, which includes a significant portion of children and adults globally. MetaLead's business model revolves around creating highly selective and effective treatments that overcome the limitations of current standards of care. The company generates revenue through the development and commercialization of these specialized medications. MetaLead's core asset was developed at the University of Zurich and is designed to capture toxic metals, detoxify the body, and promote healing. The company's innovative approach addresses a critical public health issue, providing solutions where existing treatments fall short.

Keywords: lead poisoning, medicinal chemistry, detoxification, healthcare, pharmaceuticals, neurotoxicant, selective treatment, preclinical data, public health, innovative medications.